Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an
increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been …

Fostamatinib, a recently approved Syk inhibitor used in adult primary immune
thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However …

The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed
with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for …

Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased
destruction and inadequate production of platelets that can result in bleeding, fatigue, and …

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder affecting
approximately 1 in 20,000 people. Patients typically present with clinically benign …

Rituximab and thrombopoietin receptor agonists (TPO‐RAs) have profoundly changed the
management of immune thrombocytopenia (ITP) over the last 20 years. Even if most current …

Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune
thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as …

For most of my career, the management of immune thrombocytopenia has evolved from
clinical experience rather than clinical evidence. When I was a medical student at Ohio State …

Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …